Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults

References

• O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977; 5: 1940–8.
   Google Scholar
• O'Byrne K, Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 1999; 1: 13–23.
   Google Scholar
• Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 3: 317–21.
   Google Scholar
• Brennan MF. Soft Tissue Sarcoma. In: DeVita V, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 5th edn. Philadelphia, PA: Lippincott-Raven, 1997; 1738–88.
   Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 4: 543–9.
   Google Scholar
• Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 7: 1600–8.
   Google Scholar
• Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer Hi, Blay JY, van Ossterom A, Radford JA, Svancarova L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multi-centre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 1: 61–7.
   Google Scholar
• Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studiesdose-response and schedule dependence. J Clin Oncol 1997; 6: 2378–84.
   Google Scholar
• Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarco-mas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 15: 3483–9.
   Google Scholar
• Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 12: 3225–9.
   Google Scholar
• Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer Hermans C, van Glabbecke M, Verweij J, Hogendoorn PC, Nielsen OS. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 4: 556–9.
   Google Scholar
• Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or meta-static soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 10: 2081–6.
   Google Scholar
• Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unre-sectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 12: 2824–31.
   Google Scholar
• Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxinan angiogenesis inhibitor-in patients with advanced leiomyosarco-mas. Cancer 2001; 5: 1347–8.
   Google Scholar
• Dombernowsky P, Buesa J, Pinedo HM, Santoro A, Mouridsen H, Somers R, et al. VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol 1987; 5: 579–80.
   Google Scholar
• Licht JD, Mazanet R, Loehrer PJ, Gonin R, Antman KH. Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chernother Pharrnacol 1994; 1: 79–80.
   Google Scholar
• Thigpen T, Blessing JA, Yordan E, Valea F, Vaccarello L. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 1: 120–2.
   Google Scholar
• Blair SC, Zalupski MM, Baker LH. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 1994; 6: 480–4.
   Google Scholar
• Goldstein D, Cheuvart B, Trump DL, Shiraki M, Comis RL, Tormey DC, Harris JE, Borden EC. Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 1990; 5: 420–3.
   Google Scholar
• Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995; 2: 323–32.
   Google Scholar
• Fields KK, Zorsky PE, Hiemenz JW, Kronish LE, Elfenbein GJ. Ifosfamide, carbo-platin, and etoposide: a new regimen with a broad spectrum of activity. J Clin Oncol 1994; 3: 544–52.
   Google Scholar
• Katschinski DM, Jacobson EL, Wiedemann GJ, Robins HI. Modulation of VP-16 cytotoxicity by carboplatin and 41.8 degrees C hyperthermia. J Cancer Res Clin Oncol 2001; 7: 425–32.
   Google Scholar
• Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, Denecke H, Berger H, Peter K, Wilmanns W. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol 1990; 11: 1818–29.
   Google Scholar
• van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355: 1119–25.
   PubMed Web of Science ®Google Scholar
• Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shiples W, Curran W. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radio-therapy. Int J Radiat Oncol Biol Phys 2000; 1: 13–47.
   Google Scholar
• Greenwood M. The Natural Duration of Cancer. Reports on Public Health and Medical Subjects, vol. 33. London, UK: Her Majesty's Stationary Office, 1926; 1–26.
   Google Scholar
• Issels RD, Abdel-Rahman S, Wendtner C-M, Falk MH, Kurze V, Sauer H, Aydemir U, Hiddemann W. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 2001; 13: 1599–608.
   Google Scholar
• Wendtner C-M, Abdel-Rahman S, Baumert J, Falk MH, Krych M, Santl M, Hiddemann W, Issels RD. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT- 95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001; 13: 1609–16.
   Google Scholar
• Papai Z, Bodoky G, Szanto J, Poller I, Rahoty P, Eckhardt S, Lang I, Szendroi M. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer 2000; 1: 177–80.
   Google Scholar
• Dewey WC. Interaction of heat with radiation and chemotherapy. Cancer Res 1984; 10 (Suppl): 4714s–20s.
   Google Scholar
• Van Heek-Romanowski R, Putter S, Trarbach T, Kremens B. Etoposide toxicity on human neuroblastoma cells in vitro is enhanced by preceeding hyperthermia. Med Pediatr Oncol 2001; 1: 197–8.
   Google Scholar
• Wendtner C-M, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, Hiddemann W, Issels RD. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002; 14: 3156–64.
   Google Scholar